BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim SR, Won HS, Yang JH, Sun S, Yim K, Hong M, Hong SA, Yoon JS, Chun SH, Kim KH, Ko YH. Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. Sci Rep 2022;12:1931. [PMID: 35121803 DOI: 10.1038/s41598-022-05914-4] [Reference Citation Analysis]
2 Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF. Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer. Onco Targets Ther 2021;14:1873-82. [PMID: 33737812 DOI: 10.2147/OTT.S269671] [Reference Citation Analysis]
3 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Reference Citation Analysis]
5 Mayr C, Kiesslich T, Modest DP, Stintzing S, Ocker M, Neureiter D. Chemoresistance and resistance to targeted therapies in biliary tract cancer: What have we learned? Expert Opin Investig Drugs 2022. [PMID: 35098846 DOI: 10.1080/13543784.2022.2034785] [Reference Citation Analysis]
6 Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer 2021. [PMID: 34309846 DOI: 10.1002/ijc.33751] [Reference Citation Analysis]
7 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Reference Citation Analysis]
8 Roderburg C, Loosen SH, Bednarsch J, Alizai PH, Roeth AA, Schmitz SM, Vucur M, Luedde M, Paffenholz P, Tacke F, Trautwein C, Ulmer TF, Neumann UP, Luedde T. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. Int J Mol Sci 2021;22:6569. [PMID: 34207359 DOI: 10.3390/ijms22126569] [Reference Citation Analysis]
9 Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Front Oncol 2022;12:785535. [DOI: 10.3389/fonc.2022.785535] [Reference Citation Analysis]
10 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
11 Saborowski A, Vogel A, Segatto O. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends Cancer 2021:S2405-8033(21)00226-0. [PMID: 34840108 DOI: 10.1016/j.trecan.2021.11.001] [Reference Citation Analysis]
12 Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021;74:1021-4. [PMID: 33612309 DOI: 10.1016/j.jhep.2021.01.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kai Y, Ikezawa K, Takada R, Daiku K, Maeda S, Abe Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Nagata S, Wada H, Ohkawa K. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 2021;5:712-6. [PMID: 34124390 DOI: 10.1002/jgh3.12576] [Reference Citation Analysis]
14 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Reference Citation Analysis]
15 Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs 2021;30:463-77. [PMID: 33678096 DOI: 10.1080/13543784.2021.1900821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
17 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
18 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
19 Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021;9:CD012814. [PMID: 34515993 DOI: 10.1002/14651858.CD012814.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Reference Citation Analysis]
21 Hack SP, Zhu AX. Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:1007-15. [PMID: 34459336 DOI: 10.1080/13543784.2021.1974838] [Reference Citation Analysis]